sitefansalaran International News

Global Healthcare Distribution Market is estimated to be valued at USD 1,120.67 Bn in 2025 and is expected to reach USD 1,765.68 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 6.7% from 2025 to 2032. The qualitative latest Research report (2025-2032) on the Healthcare Distribution Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves. Focused on growth and future opportunities, this report is a go-to resource for industry leaders, investors, and decision-makers. With visuals, charts, and data-driven insights, the Healthcare Distribution Market has experienced rapid growth fueled by rising demand and innovation. This analysis gives you the competitive edge with actionable strategies backed by real data. Industry Insights and Scope of the Healthcare Distribution Market This report provides a comprehensive segmentation of the Healthcare Distribution Market scope, covering product types, applications, end-user markets, key regions, and leading competitors. It offers expert insights into current market conditions, historical performance, production trends, and revenue forecasts. The financial performance of...

The European Union's trade deal with the United States could cost the pharmaceutical industry between $13 billion and $19 billion as branded medicines become subject to a tariff of 15%, analysts said on Monday. The added costs could raise prices for consumers unless pharmaceutical companies take action to mitigate the impact of the tariffs, one of the analysts said. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. Pharmaceuticals had historically been exempt from duties. Medicines are the largest European exports to the United States by value and the EU accounts for about 60% of all pharmaceutical imports to the U.S. On Sunday, European officials said that a bilateral trade deal for an across-the-board 15% tariff included pharmaceuticals, except for some generic drugs, which would be subject to no tariffs. The U.S. has been conducting a national security investigation into the pharmaceutical sector and the industry has been bracing for separate sectoral tariffs. President Donald Trump said earlier this month, before negotiating the bilateral deal, that pharmaceutical tariffs could be as high as 200%. Some Wall Street analysts said that they do not expect additional tariffs on the EU as a result of the investigation,...

U.S.-funded contraceptives worth nearly $10 million are being sent to France from Belgium to be incinerated, after Washington rejected offers from the United Nations and family planning organisations to buy or ship the supplies to poor nations, two sources told Reuters. The supplies have been stuck for months in a warehouse in Geel, a city in the Belgian province of Antwerp, following President Donald Trump's decision to freeze U.S. foreign aid in January. Get a quick look at the days breaking legal news and analysis from The Afternoon Docket newsletter. Sign up here. They comprise contraceptive implants and pills as well as intrauterine devices to help prevent unwanted pregnancies, according to seven sources and a screengrab shared by an eighth source confirming the planned destruction. The U.S. government will spend $160,000 to incinerate the stocks at a facility in France that handles medical waste, according to four of the sources with knowledge of the matter, following Trump's decision to shut down the U.S. Agency for International Development (USAID). The U.S. State Department did not respond to a request for comment on the negotiations to save the contraceptives from destruction or the plans to incinerate them. U.S. lawmakers have introduced two bills this month to prevent...

A new discovery could change how type 1 diabetes is diagnosed and managed in individuals of African descent, researchers say. In type 1 diabetes, the insulin-producing beta cells in the pancreas stop working in childhood or young adulthood. The disease has always been attributed to an autoimmune process in which the immune system produces so-called autoantibodies that mistakenly attack the pancreas. But studying 894 volunteers in Cameroon, Uganda and South Africa with youth-onset diabetes, researchers found that 65% of them did not have the usual autoantibodies typically seen in people with type 1 diabetes in other parts of the world. Nor did they have the genes that usually predispose to the disease, or features consistent with other known types of diabetes, such as type 2 and malnutrition-related diabetes. “This suggests that many young people in this region have a different form of type 1 diabetes altogether and is not autoimmune in origin,” study leader Dana Dabelea of the University of Colorado Anschutz Medical Campus said in a statement. Comparing the data to studies in the U.S., the researchers found that 15% of Black Americans diagnosed with type 1 diabetes had a form of the disease similar to the patients in Sub-Saharan Africa, characterized...

Elon Musk's brain implant company Neuralink aims to implant its chips in 20,000 people a year, and generate at least $1 billion in annual revenue by 2031, Bloomberg News reported on Wednesday, citing investor documents. The company aims to operate five large clinics within six years and offer three versions of its brain implant, including Telepathy for communication between the brain and machines, Blindsight for restoring vision, and Deep for treating tremors and Parkinson's disease, according to the report. Neuralink did not immediately respond to a Reuters request for comment. The company expects regulatory approval for its Telepathy device by 2029, with plans to perform 2,000 surgeries annually and generate $100 million in revenue, the report said. By 2030, Neuralink anticipates launching Blindsight, expanding surgeries to 10,000 per year and generating over $500 million in revenue. Neuralink, founded in 2016, has raised about $1.3 billion from investors and is valued at roughly $9 billion, the report said, citing PitchBook. The company received the U.S. Food and Drug Administration's "breakthrough" tag for its speech restoration device in May. It had received the same tag for its vision-restoring device last year. Neuralink raised $650 million in its latest funding round last month as its brain implant enters...

Hundreds of thousands of doses of mpox vaccine that the United States had promised to send to African nations are in danger of going to waste, dozens of congressional Democrats said in a letter to the U.S. State Department on Wednesday. Forty-eight Democratic members of the House of Representatives, led by Representatives Mark Pocan of Wisconsin and Sara Jacobs of California, signed the letter, saying that the vaccines may expire as they sit in warehouses, wasting the U.S. taxpayer dollars that paid for them. The letter said 800,000 doses of the vaccines are at risk, and that some 220,000 doses could be viable if the State Department begins shipping them immediately. "This is a moral, strategic, and public health failure in the making," the letter said. The State Department did not immediately respond to a request for comment. Republican U.S. President Donald Trump has made sharp cuts to foreign aid programs since beginning his second term six months ago, firing thousands of aid agency employees and contractors and throwing global humanitarian operations into chaos. The Republican-controlled Senate and House of Representatives passed legislation this month approving Trump's request for about $8 billion in foreign aid cuts. Trump has said the U.S. pays disproportionately for foreign aid,...

The World Health Organization said on Thursday systemic weaknesses in the oversight of the global pharmaceutical supply chain have resulted in medicines formulated with poisonous chemicals claiming lives and compromising the health of patients, mainly children. In a report, jointly released with the United Nations Office on Drugs and Crime, the WHO said there have been more than 300 deaths in Africa, Asia and the Pacific since 2022 linked to syrups containing industrial-grade chemicals such as diethylene glycol and ethylene glycol. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. These are often illegally substituted for pharmaceutical-grade ingredients such as propylene glycol, glycerin and sorbitol, used to formulate medicines including cough and paracetamol syrups. The agencies sounded the alarm on the lack of regulatory oversight for makers and distributors of these ingredients, and their marketing through e-commerce sites and social media. The report criticized national regulatory agencies for insufficient quality-control testing, excessive reliance on supplier-issued certificates and an overall failure to ensure traceability. It recommended steps countries could take to mitigate the risk, including making the process of reporting contaminated medicines easier and issuing timely alerts when such ingredients are detected in the supply chain.

NHS patients will be the first in Europe to benefit from a pioneering new cancer treatment which uses ultrasound to destroy tumours. The technology, known as histotripsy, offers a non-invasive treatment capable of breaking down liver cancer tissue without surgery, radiation or chemotherapy, with minimal damage to the surrounding organs, according to the Department for Health and Social Care (DHSC). First approved by US regulators in October 2023, histotripsy uses pulsed sound waves to create “bubble clouds” from gases present in the targeted tissue and tumour. When these bubbles pop, within microseconds, a shockwave is released which is capable of breaking up a mass and killing cancerous cells, while avoiding the harms of radiation and reducing the risks of bleeding, infection, and damage to surrounding non-targeted tissue. Treatment is delivered via a single session – potentially taking just 30 minutes – with limited or no pain, a quick recovery, and can be performed as a day case, according to the DHSC. The first NHS patients are set to be treated this summer at Addenbrooke’s Hospital in Cambridge, where the technology – which uses a device called an Edison System, created by US firm HistoSonics – is being debuted after a donation from the Li...

Performance-enhancing drugs are substances used to improve physical or mental performance by increasing strength, endurance, focus, or recovery. They are often utilized with the goal of achieving enhanced athletic performance, faster progress, and improved training outcomes. Their use is often associated with a strong drive for excellence and high-level achievement in competitive environments. The main product types of performance enhancing drugs include stimulants, anabolic steroids, peptide hormones, beta-2 agonists, and others. Stimulants are substances that enhance central nervous system activity, increasing alertness, energy, and physical performance. These drugs are used in various applications, including by athletes, students, military personnel, and others, and are distributed through various channels such as online stores, pharmacies, specialty stores, fitness centers, and direct sales. The end users include professional athletes, amateur athletes, bodybuilders, fitness enthusiasts, and patients with chronic illnesses. The performance enhancing drugs market size has grown strongly in recent years. It will grow from $10.79 billion in 2024 to $11.42 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to rising popularity of competitive sports, increasing awareness of physical aesthetics and body image, growing availability of PEDs through online platforms, rising use...

Dubai: Starting today, Saudi Arabia is implementing its pharmacy Saudisation policy, requiring healthcare facilities and pharmacies to meet new hiring quotas for Saudi citizens as part of the Kingdom’s Vision 2030 employment targets. The initiative, jointly implemented by the Ministry of Human Resources and Social Development and the Ministry of Health, aims to transform the labor market and increase the participation of Saudis in skilled roles. Effective Sunday, the new regulations stipulate that a minimum of 35 per cent of jobs in community pharmacies and private medical centers must be held by Saudis. The rate rises to 55 per cent in pharmaceutical factories and distribution companies, and to 65 per cent in hospital pharmacy operations. The new employment thresholds are supported by Ministerial Resolution No. (103111), dated January 26, 2025. The updated procedural guide also sets the minimum salary for registered Saudi pharmacists at SAR 7,000, while dental professionals under a related initiative must receive at least SAR 9,000 to be counted toward Saudisation quotas. The guide outlines 21 job titles covered by the policy, including general pharmacists, clinical pharmacists, pharmaceutical consultants, pharmacy sales specialists, and laboratory trainers. According to official estimates, there are between 13,000 and 14,000 pharmacies across the Kingdom, with 80–85...